1/1
11:53 am
biib
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term [Yahoo! Finance]
12/28
02:11 am
biib
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
12/20
11:15 pm
biib
Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
12/20
07:27 am
biib
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $164.00 price target on the stock, down previously from $230.00.
Low
Report
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $164.00 price target on the stock, down previously from $230.00.
12/16
07:05 am
biib
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $175.00 price target on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $175.00 price target on the stock.
12/11
11:03 pm
biib
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
12/10
08:00 am
biib
Biogen Inc. (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Bank of America Co.. They now have a $178.00 price target on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Bank of America Co.. They now have a $178.00 price target on the stock.
12/9
07:49 am
biib
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $180.00 price target on the stock, down previously from $250.00.
Low
Report
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $180.00 price target on the stock, down previously from $250.00.
12/4
06:31 pm
biib
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Low
Report
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
11/28
06:16 am
biib
Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood? [Yahoo! Finance]
Low
Report
Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood? [Yahoo! Finance]
11/27
07:31 pm
biib
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Low
Report
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
11/21
08:27 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an "outperform" rating on the stock.
11/20
02:02 pm
biib
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside [Yahoo! Finance]
Low
Report
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside [Yahoo! Finance]
11/19
01:13 am
biib
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity [Yahoo! Finance]
Low
Report
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity [Yahoo! Finance]
11/19
01:00 am
biib
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Low
Report
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
11/18
07:21 am
biib
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Needham & Company LLC to a "hold" rating. They now have a $270.00 price target on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Needham & Company LLC to a "hold" rating. They now have a $270.00 price target on the stock.
11/18
07:12 am
biib
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ [Yahoo! Finance]
Low
Report
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ [Yahoo! Finance]
11/18
04:37 am
biib
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? [Yahoo! Finance]
Low
Report
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? [Yahoo! Finance]
11/15
10:59 am
biib
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe [Yahoo! Finance]
Low
Report
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe [Yahoo! Finance]
11/15
08:04 am
biib
Biogen Inc. (NASDAQ: BIIB) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Medium
Report
Biogen Inc. (NASDAQ: BIIB) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/15
08:03 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Robert W. Baird from $294.00 to $300.00. They now have an "outperform" rating on the stock.
Medium
Report
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Robert W. Baird from $294.00 to $300.00. They now have an "outperform" rating on the stock.
11/15
05:59 am
biib
Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
Medium
Report
Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
11/14
02:29 pm
biib
European committee takes a second look at Alzheimer's drug and now says it should be approved [Yahoo! Finance Canada]
Low
Report
European committee takes a second look at Alzheimer's drug and now says it should be approved [Yahoo! Finance Canada]
11/14
02:23 pm
biib
European committee takes a second look at Alzheimer's drug and now says it should be approved [Yahoo! Finance]
Low
Report
European committee takes a second look at Alzheimer's drug and now says it should be approved [Yahoo! Finance]
11/14
01:29 pm
biib
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Low
Report
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease